Abstract
Within the last two decades of cancer research, it has become increasingly clear that viruses play an important role in the development of a significant percentage of human cancers. At present, it is recognized that viral infections are linked to at least 15% of all malignant tumors in humans and thus represent the second most common identified risk factor for cancer, exceeded only by tobacco smoking (1). Cancer-associated viruses are found in several virus families and encompass both DNA and RNA viruses (Table 1). In the past few years, significant progress has been made towards elucidation of the molecular mechanisms through which viruses contribute to cell transformation. Different tumor viruses target common cellular pathways for growth control, but also exhibit unique (virus-specific) properties that contribute to oncogenesis.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
zur Hausen, H. (I 991) Viruses in human cancers. Science 254: 1167 1173.
zur Hausen, H. (1996) Papillomavirus infections: a major cause of human cancers. Biochim. Biophys. Acta 1288: F55 - F78.
Howley, P. (1996) Papillomavirinae: the viruses and their replication. In: Fields Virology (Fields, B. N., Knipe, D. M., Howley, P. M., eds.), Lippincott-Raven, Philadelphia, pp. 2045–2076.
Dollard, S. C., Wilson, J. L., Demeter, L. M., Bonnez, W., Reichman, R. C., Borker, T. R., et al. (1992) Production of human papillomavirus and modulation of the infectious program in epithelial raft cultures. Genes Dev. 6: 1131–1142.
Meyers, C., Frattini, M. G., Hudson, J. B., and Laimins, L. A. (1992) Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science 257: 971–973.
Pisani, P., Parkin, D. M., and Ferlay, J. (1993) Estimates of the worldw ide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int. J. Cancer 54: 594–606.
Bosch, F. X., Munoz, N., de Sanjosé, S., Izarzugaza, I., Gili, M., Viladiu, P., et al. (1992) Risk factors for cervical cancer in Columbia and Spain. Int. J. Cancer 52: 750–758.
Koutsky, L. A., Holmes, K. K., Critchlow, C. W., Stevens, C. E., Paavonen, J., Beckmann, A. M., et al. (1992) A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N. Engl. J. Med. 327: 1271–1278.
Dillner, J., Lehtinen, M., Bjorge, T., Luostarinen, T., Youngman L., Jell um, E., et al. (1997) Prospective seroepidemiologic study of human papillomavirus infections as a risk factor for invasive cervical cancer. J. Natl. Cancer Inst. 89: 1293–1299.
Schwarz, E., Freese, U. K., Gissmann, L., Mayer, W., Roggenbuck, B., Stromlau, A., et al. (1985) Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 31: 111–114.
von Knebel Doeberitz, M. (1992) Papillomaviruses in human disease: Part II. Molecular biology and immunology ofpapillomavirus infections and carcinogenesis. Eue. J. Med. 1: 485–491.
Hoppe-Seyler, F. and Butz, K. (1994) Cellular control of human papillomavirus oncogene transcription. Mol. Carcinogenesis 10: 134–141.
Durst, M., Glitz, D., Schneider, A., and zur Hausen, H. (1992) Human papillomavirus type 16 (HPV 16) gene expression and DNA replication in cervical neoplasia: analysis by in situ hybridization. Virology 189: 132–140.
Thierry, F. and Yaniv, M. (1987) The BPV 1-E2-trans-acting protein can be either an activator or a repressor of the HPV 18 regulatory region. EMBO J. 6: 3391–3397.
Jeon, S. and Lambert, P. F. (1995) Integration of HPV 16 DNA into the human genome leads to increased stability of E6/E7 mRNAs: implications for cervical carcinogenesis. Proc. Natl. Acad. Sci. USA 92: 1654–1658.
Hoppe-Seyler, F. and Scheffner, M. (1997) E6 protein. In: Papillomaviruses in Human Cancer: The Role of the E6 and E7 Oncoproteins ( Tommassino, M., ed.), Landes Bioscience, Austin, TX, pp. 71–102.
Jones, D. L. and Munger, K. (1996). Interactions of the human papillomavirus E7 protein with cell cycle regulators. Semin. Cancer Biol. 7: 327–337.
Kubbutat, M. H. G. and Vousden. K. H. (1996) Role of the E6 and E7 oncoproteins in HPV-induced anogenital malignancies. Semin. Virol. 7: 295–304.
Scheffner, M., Werness, B. A., Huibregtsc, J. M., Levine, A. J., and Howley, P. M. (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129–1136.
Lane, D. P. (1992) p53, guardian ofthe genome. Nature 358: 15–16.
Fritsche, M., Haessler, C., and Brandner, G. (1993) Induction of nuclear accumulation ofthe tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 8: 307–318.
Levine, A. J. (1997) p53, the cellular gatekeeper for growth and division. Cell 88: 323–331.
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., et al. (1993) WAF-1, a potential mediator or p53 tumor suppression. Cell 75: 817–825.
Miyashita, T. and Reed, J. C. (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293–299.
Caelles, C., Heimberg, A., and Karin, M. (1994) p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370: 220–223.
Mietz, J. A., Unger, T., Huibregtse, J. M., and Howley, P. M. (1992) The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J. 11: 5013–5020.
Hoppe-Seyler, F. and Butz, K. (1993) Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53. J. Viral. 67: 3111–3117.
Kessis, T. D., Slebos, R. J., Nelson, W. G., Kastan, M. B., Plunkett, B. S., Han, S. M., et al. (1993) Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc. Natl. Acad. Sci. USA 90: 3988–3992.
White A. E,. Livanos, E. M., and Tlsty, T. (1994) Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes Dev. 8: 666–677.
Scheffner, M., Munger, K., Byrne, J. C., and Howley, P. M. (1991) The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl. Acad. Sci. USA 88: 5523–5527.
Park, D. J., Wilczynski, S. P., Paquette, R. L., Miller, C. W., and Koeffler, H. P. (1994) p53 mutations in HPV-negative cervical carcinoma. Oncogene 9: 205–210.
Butz, K., Shahabeddin, L., Geisen, C., Spitkovsky, D., Ullmann, A., and Hoppe-Seyler, F. (1995) Functional p53 protein in human papillomavirus-positive cancer cells. Oncogene 10: 927–936.
Butz, K., Geisen. C., Ullmann, A., Spitkovsky, D., and HoppeSeyler, F. (1996) Cellular responses of HPV-positive cancer cells to genotoxic anti-cancer agents: repression of E6/E7-oncogene expression and induction of apoptosis. Int. J. Cancer 68: 506–513.
Pim, D., Storey, A., Thomas, M., Massimi, P., and Banks, L. (1994) Mutational analysis of HPV18–E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells. Oncogene 9: 1869–1876.
Spitkovsky, D., Aengeneyndt, F., Braspenning, J., and von Knebel Doeberitz, M. (1996) p53-independent growth regulation of cervical cancer cells by the papillomavirus E6 oncogene. Oncogene 13: 1027–1035.
Lamberti, C., Morrissey, L. C., Grossman, S. R., and Androphy, E. J. (1990) Transcriptional transactivation by the human papillomavirus E6 zinc finger protein. EMBO J. 9: 1907–1913.
Sedman, S. A., Barbosa, M. S., Vass, W. C., Hubbert, N. L., Haas, J. A., Lowy, D. R., et al. (1991) The full length E6 protein of human papillomavirus type 16 has transforming and trans-activating activities and cooperates with E7 to immortalize keratinocytes in culture. J. Virol. 65: 4860–4866.
Pan, H. and Griep, A. E. (1995) Temporally distinct patterns of p53- dependent and p53-independent apoptosis during mouse lens development. Genes Dev. 9: 2157–2169.
Klingelhutz, A. J., Foster, S. A., and McDougall, J. K. (1996) Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 380: 79–82.
Keen, N., Elston, R., and Crawford L. (1994) Interaction of the E6 protein of human papillomavirus with cellular proteins. Oncogene 9: 1493–1499.
Chen, J. J., Reid, C. E., Band, V., and Androphy, E. J. (1995) Interaction of papillomavirus E6 oncoproteins with a putative calcium-binding protein. Science 269: 529–531.
Munger, K. and Phelps, W. C. (1993) The human papillomavirus E7 protein as a transforming and transactivating factor. Biochim. Biophys. Acta 1155: 111–123.
Weinberg, R. A. (1995) The retinoblastoma protein and cell cycle control. Cell 81: 323–330.
LaThangue, N. B. (1994) DRTF1/E2F: an expanding family of heterodimeric transcription factors implicated in cell cycle control. Trends Biochem. Sci. 19: 108–114.
Huang, P. S., Patrick, D. R., Edwards, G., Goodhart, P. J., Huber, H. E., Miles, L., et al. (1993) Protein domains governing interactions between E2F, the retinoblastoma gene product, and human papillomavirus type 16 E7 protein. Mol. Cell. Biol. 13: 953–960.
Boyer, S. N., Wazer, D. E., and Band, A. (1996) E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 56: 4620–4624.
Jones, D. L., Thompson, D. A., and Munger, K. (1997) Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV Type 16 E7-induced apoptosis. Virology 239: 97–107.
Funk, J. O., Waga, S., Harry, J. B., Espling, E., Stillman, B., and Galloway, D. A. (1997) Inhibition of cdk activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev. 11: 2090–2100.
Jones, D. L., Alani, R. M., and Munger, K. (1997) The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21 CIP i-mediated inhibition of cdk2. Genes Dev. 11: 2101–2111.
Cheng, S., Schmidt-Grimminger, D.-C., Murant, T., Broker, T. R., and Chow, L. T. (1995) Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes Dev. 9: 2335–2349.
Edmonds, C. and Vousden, K. H. (1989) A point mutational analysis of human papillomavirus type 16 E7 protein. J. Virol. 63: 2650–2656.
Banks, L., Edmonds, C., and Vousden, K. (1990) Ability of HPV16 E7 protein to bind RB and induce DNA synthesis is not sufficient for efficient transforming activity in NIH 3T3 cells. Oncogene 5: 1383–1389.
Phelps, W. C., Munger, K., Lee, C. L., Barnes, J. A., and Howley, P. M. (1992) Structure-function analysis of the human papillomavirus type 16 E7 protein. J. Virol. 66: 2418–2427.
Dyson, N., Guida, P., Munger, K., and Harlow, E. (1992) Homologous sequences in adenovirus El A and human papillomavirus E7 proteins mediate interaction with the same set of proteins. J. Virol. 66: 6893–6902.
Tommasino, M., Adamczewski, J. P., Carlotti, F., Barth, C. F., Manetti, R., Contorni, M., et al. (1993) HPV16 E7 protein associates with the protein kinase p33CDK2 and cyclin A. Oncogene 8: 195–202.
McIntyre, M. C., Ruesch, M. N., and Laimins, L. A. (1996) Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a complex with cdk2 and p107. Virology 215: 73–82.
Zerfass-Thome, K., Zwerschke, W., Mannhardt, B., Tindle, R., Botz, J. W., and Jansen-Dürr, P. (1996) Inactivation of the cdk inhibitor p27KIPt by the human papillomavirus type 16 E7 oncoprotein. Oncogene 13: 2323–2330.
Vousden, K. H., Vojtesek, B., Fisher, C., and Lane, D. (1993) HPV I 6-E7 or adenovirus E l A can overcome the growth arrest of cells immortalized with a temperature-sensitive p53. Oncogene 8: 1697–1702.
Demers, G. W., Foster, S. A., Halbert, C. L., and Galloway, D. A. (1994) Growth arrest by induction of p53 in DNA-damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc. Natl. Acad. Sci. USA 91: 4382–4386.
Hickman, E. S., Picksley, S. M., and Vousden, K. H. (1994) Cells expressing HPV16 E7 continue cell cycle progression following DNA damage induced p53 activation. Oncogene 9: 2177–2181.
Slebos, R. J. C., Lee, M. H., Plunkett, B. S., Kessis, T. D., Williams, B. O., Jacks, T., Hedrick, L., et al. (1994) p53-dependent Gl-arrest involves pRb-related proteins and is disrupted by the human papillomavirus E7 oncoprotein. Proc. Natl. Acad. Sci. USA 91:5320–5324.
Chuang, L. S.-H., Ian, H.-1., Koh, T.-W., Ng, H.-H., Xu, G., and Li, B. F. L. (1997). Human DNA-(cytosine-5) methyltransferasePCNA complex as a target for p21 WAF 1. Science 277: 1996–2000.
Waga, S., Hannon, G. J., Beach, D., and Stillman, B. (1994) The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369: 547–578.
Lam E. W.-F., Morris, J. D. H., Davies, R., Crook, T., Watson, R. J., and Vousden, K. H. (1994) HPV16 E7 oncoprotein deregulates B-myb expression: correlation with targeting of p107/E2F complexes. EMBO J. 13: 871–878.
Zerfass, K., Schulze, A., Spitkovsky, D., Friedman, V., Henglein, B., and Jansen-Dürr, P. (1995) Sequential activation of cyclin E and cyclin A gene expression by human papillomavirus type 16 E7 through sequences necessary for transformation. J. Virol. 69: 6389–6399.
Antinore, M. J., Birrer, M. J., Patel, D., Nader, L., and McCance, D. J. (1996) The human papillomavirus type 16 E7 gene product interacts with and trans-activates the AP1 family of transcription factors. EMBO J. 15: 1950–1960.
Massimi, P., Pim, D., Storey, A., and Banks, L. (1996) HPV-16 E7 and adenovirus Ela complex formation with TATA box binding protein is enhanced by casein kinase II phosphorylation. Oncogene 12: 2325–2330.
Hawley-Nelson, P., Vousden, K. H., Hubbert, N. L., Lowy, D. R., and Schiller, J. T. (1989) HPV16 E6 and E7 proteins cooperate to immortalise human foreskin keratinocytes. EMBO J. 8: 3905–3910.
Munger, K., Phelps, W. C., Bubb, V., Howley, P. M., and Schlegel, R. (1989) The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 63: 4417–4421.
Puthenveettil, J. A., Frederickson, S. M., and Reznikoff, C. A. (1996) Apoptosis in human papillomavirus 16 E7- but not E6-immortalized uroepithelial cells. Oncogene 13: 1123–1131.
Jablonska, S. and Majewski, S. (1994) Epidermodysplasia verruciformis: immunological and clinical aspects. Curr. Topics Microbiol. Immunol. 186: 157–175.
Shahamanin, V., zur Hausen, H., Lavergne, D., Proby, C. M., Leigh,I. M., Neumann, C., et al. (1996) Human papillomavirus infections in non-melanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients. J. Natl. Cancer Inst. 88: 802–811.
Robinson, W. S. (1994) Molecular events in the pathogenesis of hepadnavirus-associated hepatocellular carcinoma. Ann. Rev. Med. 45: 297–323.
Ganem, D. (1996) Hepadnaviridae and their replication. In: Fields Virology ( Fields, B. N., Knipe, D. M., and Howley, P. M., ed.), Lippincott-Raven, Philadelphia, pp. 2703–2737.
Hollinger, F. B. (1996) Hepatits B virus. In: Fields Virology ( Fields, B. N., Knipe, D. M., and Howley, P. M., ed.), Lippincott-Raven, Philadelphia, pp. 2739–2807.
Beasley, R. P. (1988) Hepatitis B virus. The major etiology ofhepatocellular carcinoma. Cancer 61: 1942–1956.
Pisani, P., Parkin, D. M., Munoz, N., and Ferlay, J. (1997) Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol. Biomark. Prevent. 6: 387–400.
Shirakata, Y., Kawada, M., Fujiki, Y., Sano, H., Kobayashi, M., and Koike, K. (1989) The X gene of hepatitis B virus induced growth stimulation and tumorigenic transformation of mouse NIH 3T3 cells. Jpn. J. Cancer Res. 80: 617–621.
Höhne, M., Schäfer, S., Seifer, M., Feitelson, M. A., Paul, D., and Gerlich, W. H. (1990) Malignant transformation of immortalised transgenic hepatocytes after transfection with hepatitis B virus DNA. EMBO J. 9: 1137–1145.
Kim, S., Koike, K., Saito, I., Myamura, F., and Ray, G. (1991) HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 351: 317–320.
Doria, M., Klein, N., Lucito, R., and Schneider, R. J. (1995) The hepatitis B virus Hbx protein is a dual specificity cytoplasmic activator of Ras and nuclear activator of transcription factors. EMBOJ. 14: 4747–4757.
Koike, K. and Takada, S. (1995) Biochemistry and functions of hepatitis B virus X protein. Intervirology 38: 89–99.
Feitelson, M. A., Zhu, M., Duan, X.-L., and London, W. T. (1993) Hepatitis X-antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 8: 1109–1117.
Wang, X. W., Forrester, K., Yeh, H., Feitelson, M. A., Gu, J.-R., and Harris, C. C. (1994) Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl. Acad. Sci. USA 91: 2230–2234.
Wang, X. W., Tgibson. M. K., Vermeulen, W., Yeh, H., Forrester, K., Sturzbecher, H.-W., et al. (1995) Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res. 55: 60126016.
Ueda, H., Ullrich, S. J., Gangemi, J. D., Kappel, C. A., Ngo, L., Feitelson, M. A., et al (1995) Functional inactivation but not structural mutation of p53 causes liver cancer. Nature Genet. 9: 41–47.
Takada, S., Kaneniwa, N., Tsuchida, N., and Koike, K. (1997). Cytoplasmic retention of the p53 tumor suppressor gene product is observed in the hepatitis B virus X gene-transfected cells. Oncogene 15: 1895–1901.
Hager. C., Velhagen, I., Zentgraf, H., and Schröder, C. H. (1991) Diversity of hepatitis B virus X gene-related transcripts in hepatocellular carcinoma: a novel polyadenylation site on viral DNA. J. Virol. 65: 4284–4291.
Hildt, E., Hofschneider, P. H., and Urban, S. (1996) The role of hepatitis B virus (HBV) in the development of hepatocellular carcinoma. Semin. Virol. 7: 333–347.
Dejean, A., Bouguerelet, L., Grzeschik, K. H., and Tiollais, P. (19861 Hepatitis B virus DNA integration in a sequence homologous to v-erb-A and steroid receptor genes in a hepatocellular carcinoma. Nature 322: 70–72.
Wang, J., Cenivesse, X., Henglein, B., and Brechot, C. (1990) Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature 343: 555–557.
Lieber, C. S., Garro, A., Leo, M. A., Mak, K. M., and Worner, T. (1986) Alcohol and cancer. Hepatology 6: 1005–1009.
Jhappan, C., Stahle, C., Harj ins, R. N., Fausto, N., Smith, G. H., and Merlino, G. T. (1990) TGF-a overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell 61: 1137–1 146.
Houghton, M. (1996) Hepatitis C viruses. In: Fields Virology ( Fields, B. N., Knipe, D. M., and Howley, P. M., eds.), Lippincott-Raven, Philadelphia, pp. 1035–1058.
Purcell, R. (1997). The hepatitis C virus: Overview. Hepatology 26: 11S - 14S.
Choo, Q.-L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W. and Houghton, M. (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244: 359–362.
Hoofnagle, J. H. (1997) Hepatitis C: the clinical spectrum of disease. Hepatology 26: 15S - 20S.
Farci, P., Alter, H. J., Govindarajan, S., Wong, D. C., Engle, R., Lesniewski, R. R., et al. (1992) Lack of protective immunity against reinfection with hepatitis C virus. Science 258: 135–140.
National Institutes of Health consensus development conference panel statement: management of hepatitis C. (1997) Hepatology 26:2S–10S.
Di Bisceglie, A. M. (1997) Hepatitis C and hepatocellular carcinoma. Hepatology 26: 34S - 38S.
Ray, R. B., Lagging, L. M., Meyer, K., and Ray, R. (1996) Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. J. Virol. 70:4438444 3.
Bhandari, B. N. and Wright, T. L. (1995) Hepatitis C: an overview. Ann. Rev. Med. 46: 309–317.
Kieff, E. (1996) Epstein-Barr virus and its replication. In: Fields Virology ( Fields, B. N., Knipe, D. M., and Howley, P. M., eds.), Lippincott-Raven Publishers, Philadelphia, pp. 2343–2396.
Rickinson, A. B. and Kieff, F. (1996) Epstein Barr virus. ln: Fields Virology (Fields, B. N., Knipe, D. M., and Howley, P. M., eds.), Lippincott-Raven, Philadelphia, pp. 2397–2446.
Niedobitek, G. and Young, L. S. (1994) Epstein-Barr virus persistance and virus-associated tumors. Lancet 343: 333–335.
Wang, D., Liebowitz, D., and Kieff, E. (1985) An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43: 831–840.
Baichwal, V. R. and Sugden, B. (1988) Transformation of BALB 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. Oncogene 2: 461–467.
Dawson, C. W., Rickinson, A. B., and Young, L. S. (1990) Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature 344: 777–780.
Fahraeus, R., Rymo, L., Rhim, J. S., and Klein, G. (1990) Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus. Nature 345: 447 449.
Knecht, H., Berger, C., Al-Homsi, A. S., McQuain, C., and Brousset, P. (1997) Epstein-Barr virus oncogenesis. Crit. Rev. Oncol. Hematol. 26: 1 17 135.
Gires, O., Zimber-Strobl, U., Gonnella, R., Ueffing, M., Marschall, G., Zeidler, R., et al. (1997) Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J. 16: 6131–6140.
Wilson, J. B. and Levine, A. J. (1992) The oncogenic potential of Epstein-Barr virus nuclear antigen 1 in transgenic mice. Curr. Top. Microhiol. Immunol. 182: 375–384.
Srinivas, S. K. and Sixbey, J. W. (1995) Epstein-Barr virus induction of recombinase-activating genes RAG1 and RAG2. J Virol. 69: 8155–8158.
Henkel, T., Liang, P. D., Hayward, S. D., and Peterson, M. G. (1994) Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa. Science 265: 92–95.
Zimber-Strobl, U., Strobl, L. J., Meitinger, C., Hinrichs, R., Sakai, T., Furukawa, T., et al. (1994) Epstein-Barr virus nuclear antigen 2 exerts its transactivating function through interaction with recombination signal binding protein RBP-J kappa, the homologue of Drosophila suppressor of hairless. EMBO J. 13: 4973–4982.
Laux, G., Adam,. B., Strobl. L. J., and Moreau-Gachelin, F. (I 994) The Spi/PU.1 and Spi-B ets family transcription factors and the recombination signal binding protein RBP-J kappa interact with an Epstein-Barr virus nuclear antigen 2 responsive cis-element. EMBO J. 13: 5624–5632.
Kempkes, B., Spitkovsky, D., Jansen-Dürr, P., Ellwart, J. W., Kremmer, E., Delecluse, H.-J., et al. (1995). B-cell proliferation and induction of early GI -regulating proteins by Epstein-Barr virus mutants conditional for EBNA2. EMBO J. 14: 88–96.
Parker, G. A., Crook, T., Bain, M., Sara, E. A., Farrell, P. J., and Allday, M. J. (1996) Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus EIA and papillomavirus E7. Oncogene 13: 2541–2549.
Szekely, L., Selivanova, G., Magnusson, K. P., Klein, G., and Wiman, K. G. (1993) EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc. Natl. Acad. Sci. USA 90: 5455–5459.
Allday, M. J., Sinclair, A., Parker, G., Crawford, D. H., and Farrell, P. J. (1995) Epstein-Barr virus efficiently immortalizes human B cells without neutralizing the function of p53. EMBO J. 7: 1382–1391.
Oujedans, J. J., Jiwa, N. M., van deb Brule, A. J. C., Gräser, F. A., Horstman, A., Vos, W., et al. (1995) Detection of heterogeneous Epstein-Barr virus gene expression patterns within individual post-transplantation lymphoproliferative disorders. Am. J. Pathol. 147: 923–933.
Magrath, I. (1990) The pathogenesis of Burkitt’s lymphoma. Adv. Cancer Res. 55: 133–269.
Klein, G. and Klein, E. (1985) Evolution of tumors and the impact of molecular oncology. Nature 315: 190–195.
Lenoir, G. and Bornkamm, G. W. (1986) Burkitt’s lymphoma: a human cancer model for the study of the multistep development of cancer: proposal for a new scenario. In: Advances in Viral Oncol- ogy, vol. 7 (Klein, G., ed.), Raven Press, New York, pp. 173–206.
Geser, A., de The, G., Lenoir, G., Day, N. E., and Williams, E. H. (1982) Final case reporting from the Ugandian prospective study of the relationship between EBV and Burkitt’s lymphoma. Int. J. Cancer 29: 397–400.
Rowe, M., Rowe, D. T., Gregory, C. D., Young, L. S., Farrell, P. J., Rupani, H., et al. (1987) Differences in B-cell growth phenotype reflect novel patterns of Epstein-Ban virus latent gene expression in Burkitt’s lymphoma cells. EMBO J. 6: 2743–2751.
Levitskaya, J., Coram, M., Levitsky, V., Imreh, S., Steigerwald-Mullen, P. M., Klein, G., et al. (1995) Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375: 685–688.
Simuzu, N., Tanabe-Kochikura, A., Kuroiwa, Y., and Takada, K. (1994) Isolation of Epstein-Ban virus (EBV)-negative cell clones from the EBV-positive Burkitt’s lymphoma BL line Akata: Malignant phenotypes of BL cells are dependent on EBV. J. Virol. 68: 6069–6073.
Lam, K. M. C. and Crawford, D. H. (1991) The oncogenic potential of Epstein-Barr virus. Crit. Rev. Oncogenesis 2: 229–245.
Polack, A., Hortnagel, K., Pajic, A., Baier, B., Falk, M., Mautner, J., et al. (1996) c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein. Proc. Natl. Acad. Sci. USA 93: 10411–10416.
Razzouk, B. I., Srinivas, S., Sample, C. E., Singh, V., and Sixbey, J. W. (1996) Epstein-Barr virus DNA recombination and loss in sporadic Burkitt’s lymphoma. J. Infect. Dis. 173: 529–535.
List, A. F., Greco, F. A., and Vogler, L. B. (1987) Lymphoproliferative diseases in immunocompromised hosts: the role of Epstein-Ban virus. J. Clin. Oncol. 5: 1673–1689.
Oudejans, J. J., Jiwa, N. M., van den Brule, A. J. C., and Meijer, C. J. L. M. (1997). Epstein-Barr virus and its possible role in the pathogenesis ofB-cell lymphomas. Crit. Rev. Oncol. Hematol. 25: 127–138.
Sullivan, J. L. and Woda, B. A. (1989) X-linked lymphoproliferative syndrome. Immunodeficiency Rev. 1: 325–347.
Starzl, T. E., Nalesnik, M. A., Porter, K. A., Ho, M., Iwatsuki, S., Griffith, B. P., et al. (1984) Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1: 583–587.
Larson, R. S., Scott, M. A., McCurley, T. L., and Vnencak-Jones C. L. (1996) Microsatellite analysis of posttransplant lymphoproliferative disorders: determination of donor/recipient origin and identification of putative lymphomagenic mechanism. Cancer Res. 56: 4378–4381.
Hamilton-Dutoit, S. J., Pallesen, G., Franzmann, M. B., Karkov, J., Black, F., Skinhoj, P., and Pedersen, C. (1991) AIDS-related lymphoma: Histopathology, immunophenotype, and association with Epstein-Ban virus as demonstrated by in situ nucleic acid hybridization. Am. J. Pathol. 138: 149–163.
Pallesen, G., Hamilton-Dutoit, S. J., and Shou, X. (1993) The association of Epstein-Barr virus (EBV) with T-cell lymphoproliferation and Hodgkin’s disease: two new developments in the EBV field. Adv. Cancer Res. 62: 179–239.
Meijer, C. J. L. M., Jiwa, N. M., Dukers, D. F., Oudejans, J. J., de Bruin, P. C., Walboomers, J. M. M., et al. (1996) Epstein-Barr virus and human T-cell lymphomas. Semin. Cancer Biol. 7: 191–196.
Wolf, J. and Diehl, V. (1994) Is Hodgkin’s disease an infectious disease? Ann. Oncol. 5: S105 - S111.
Herbst, H. (1996) Epstein-Barr virus in Hodgkin’s disease. Semin. Cancer Biol. 7: 183–189.
Gutensohn, N. M. and Cole, P. (1980) Epidemiology of Hodgkin’s disease. Semin. Oncol. 7: 92–102.
zur Hausen, H., Schulte-Holthausen, H., Klein, G., Henle, W., Henle, G., Clifford, P., and Santesson, L. (1970) EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 228: 1056–1058.
Niedobitek, G., Agathanggelou, A., and Nicholls, J. M. (1996) Epstein-Barr virus infection and the pathogenesis of nasopharyngeal carcinoma: viral gene expression, tumour cell phenotype, and the role of the lymphoid stroma. Semin. Cancer Biol. 7: 165–174.
Henle, W., Ho, J. H. C., Henle, G., Chau, J. C. W., and Kwan, H. C. (1977) Nasopharyngeal carcinoma: significance of changes in Epstein-Barr virus-related antibody patterns following therapy. Int. J. Cancer 20: 663–672.
de The, G. and Zeng, Y. (1986) Population screening for EBV markers: towards improvement of nasopharyngcal carcinoma control. In: The Epstein-Barr Virus ( Epstein, M. A. and Achog, B. G., eds.), John Wiley and Sons, New York, pp. 237–248.
Osato, T. and Imai, S. (1996) Epstein-Ban virus and gastric carcinoma. Semin. Cancer Biol. 7: 175–182.
Chang, Y., Cesarman, E., Pessin, M. S., Lee, F., Culpepper, C., Knowles, D. M., et al. (1994) Identification of herpesvirus-like sequences in AIDS-associated Kaposi’s sarcoma. Science 266: 1865–1869.
Renne, R., Zhong, W., Herndier, B., McGrath, M., Kedes, D., and Ganem, D. (1996) Lytic growth of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) in a cultured B-cell lymphoma line. Nature Med. 2: 342–346.
Russo, J. J., Bohenzky, R. A., Cheien, M. C., Chen, J., Yan. M., Maddalena, D., et al. (1996) Nucleotide sequence of the Kaposi’s sarcoma-associated herpesvirus (HHV8). Proc. Natl. Acad. Sci. USA 93: 14862–14867.
Biesinger, B., Müller-Fleckenstein, I., Simmer, B., Lang, G., Wittmann, S., Platzer, E., et al. (1992) Stable growth transformation of human T-lymphocytes by herpesvirus saimiri. Proc. Natl. Acad. Sci. USA 89: 3116–3119.
Neipel, F., Albrecht, J.-C., and Fleckenstein, B. (1997) Cell homologous genes in the Kaposi’s sarcoma-associated rhadinovirus human herpesvirus type 8: determinants of its pathogenicity? J. Virol. 71: 4187–4192.
Cheng, E. H. Y., Nicholas, J., Bellows, D., Hayward, G. S., Guo, H. G., Reitz, M. S., et al. (1997) A Bel-2 homolog encoded by Kaposi’s sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak. Proc. Natl. Acad. Sci. USA 94: 690–694.
Chang, Y., Moore, P. S., Talbot, S. J., Boshoff, C. H., Zarkowska, T., Godden-Kent, D., et al. (1996) Cyclin encoded by KS herpesvirus. Nature 382: 410.
Swanton, C., Mann, D. J., Fleckenstein, B., Neipel, F., Peters, G., and Jones, N. (1997) Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature 390: 184–187.
Boshoff, C., Endo, Y., Collins, P. D., Takeuchi, Y., Reeves, J. D., Schweickart, V. L., et al. (1997) Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science 278: 290–294.
Arvanitakis, L., Geras-Raaka, E., Varma, A., Gerhengorn, M. C., and Cesarman, E. (1997) Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature 385: 347–350.
Bais, C., Santomasso, B., Coso, O., Arvanitakis, L., Raaka, E. G., Gutkind, J. S., et al. (1998) G-protein-coupled receptor of Kaposi’s sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 391: 86–89.
Roth, W. K., Brandstetter, H., and Sturzl, M. (1992) Cellular and molecular features of HIV-associated Kaposi’s sarcoma. AIDS 6: 895–913.
Ensoli, B., Barillari, G., and Gallo, R. C. (1992) Cytokines and growth factors in the pathogenesis of AIDS-associated Kaposi’s sarcoma. Immunol. Rev. 127: 147–155.
Beral, V., Peterman, T. A., Berkelman, R. L., and Jaffe, H. W. (1990) Kaposi’s sarcoma among patients with AIDS: a sexually transmitted infection? Lancet 335: 123–128.
Ganem, D. (1996) Human herpesvirus 8 and the biology of Kaposi’s sarcoma. Semin. Virol. 7: 325–332.
Ensoli, B., Barillari, G., Salahuddin, S. Z., Gallo, R. C., and Wong-Staal, F. (1990) Tat protein of HIV-1 stimulates growth of cells derived from Kaposi’s sarcoma lesions of AIDS patients. Nature 345: 84–86.
Ganem, D. (1997) KSHV and Kaposi’s sarcoma: the end of the beginning? Cell 91: 157–160.
Gillison, M. L. and Ambinder, R. F. (1997) Human herpesvirus-8. Curr. Opin. Oncol. 9: 440–449.
Geraldo, G., Beth, E., and Haguenau, F. (1972) Herpes-type virus particles in tissue culture of Kaposi’s sarcoma from different geographic regions. J. Natl. Cancer Inst. 49: 1509–1513.
Lennette, E. T., Blackbourn, D. J., and Levy, J. A. (1996) Antibodies to human herpesvirus type 8 in the general population and in Kaposi’s sarcoma patients. Lancet 348: 858–861.
Soulier, J., Grollet, L., Oksenhendler, E., Cacoub, P., CazalsHatem, D., Babinet, P., et al. (1995) Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood 86: 1276–1280.
Cesarman, E., Chang, Y., Moore, P. S., Said, J. W., and Knowles D. M. (1995) Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N. Engl. J. Med, 322: 1186–1191.
Rettig, M. B., Ma, H. J., Vescio, R. A., Pold, M., Schiller, G., Belson, D., et al. (1997). Kaposi’s sarcoma-associated herpesvirus infection of bone-marrow dendritic cells from multiple myeloma patients. Science 276: 1851–1854.
Cann, A. J. and Chen, I. S. Y. (1996) Human T-cell leukemia virus types I and II. In: Fields Virology ( Fields, B. N., Knipe, D. M., and Howley, P. M., eds.), Lippincott-Raven, Philadelphia, pp. 1849–1880.
Kondo. T., Kono, H., Nonaka, H., Yoshida, R., Bando, F., Inoue, H., et al. (1987) Risk of adult T-cell leukemia lymphoma in HTLVI carriers. Lancet 2:159.
Rosenblatt, J. D., Golde, D. W., Wachsman, W., Giorgi, J. V., Jacobs. A., Schmidt. G. M., et al. (1986) A second isolate of HTLVII associated with atypical hairy-cell leukemia. N. Engl. J. Med. 315: 372–377.
Yamamoto, N., Okada, M., Koyanagi, Y., Kannagi, Y., and Hinuma, Y. (1982) Transformation of human leukocytes by cocultivation with an adult T-cell leukemia virus producer cell line. Science 217: 737–739.
Popovic, M., Lange-Wantzin, G., Sarin, P. S., Mann, D., and Gallo, R. C. (1983) Transformation of human umbilical cord blood T cells by human T cell leukemia/lymphoma virus. Proc. Natl. Acad. Sci. USA 80: 5402–5406.
Seiki, M., Eddy, R., Shows, T. B., and Yoshida, M. (1984) Nonspecific integration of the HTLV provirus genome into adult T-cell leukaemia cells. Nature 309: 640–642.
Yoshida, M. (1996) Multiple targets of HTLV-I for dysregulation of host cells. Semin. Virol. 7: 349–160.
Grassmann, R., Dengler, C., Müller-Fleckenstein, I., Fleckenstein, B., McGuire, K., Dokhlear, M., et al. (1989) Transformation to continuous growth of primary human T-lymphocytes by human T cell leukemia virus type I X-region genes transduced by a herpes-virus saimiri vector. Proc. Natl. Acad. Sci. USA 86: 3351–3355.
Nerenberg, M., Hinrichs, S. H., Reynolds, R. K., Khoury, G., and Jay, G. (1987) The tat gene of human T lymphotropic virus type I induces mescnchymal tumors in transgenic mice. Science 237: 1324–1329.
Jeang, K. T., Widen, S. G., Semmes IV, O. J., and Wilson, S. H. (1990) HTLV-I trans-activator protein, Tax, is a trans-repressor of the human beta-polymerase gene. Science 247: 1082–1084.
Greene, W. C., Leonard, W. J., Wano, Y., Svetlik, P. B., Peffer, N. J., Sodrosky, J. G., et al. (1986) Trans-activator gene of HTLV II induces IL-2 receptor and IL-2 cellular gene expression. Science 232: 877–881.
Maruyama, M., Shibuya, H., Harada, H., Hatakeyama, M., Seiki, M., Fujita, T., et al. (1987) Evidence for aberrant activation of the intcrleukin-2 autocrine loop by HTLV-I-encoded p4Ox and T3/Ti complex triggering. Celi 48: 343–350.
Kimata, J. T. and Ratner, L. (1991) Temporal regulation of viral and cellular gene expression during human T-Iymphotropic virus type I-mediated lymphocyte immortalization. J. Virol. 65: 4398–4407.
Suzuki, T., Kitao, S., Matsushime, H., and Yaoshida, M. (1996) HTLV-1 Tax protein interacts with cyclin-dependent kinase inhibitor p161“K4A and counteracts its inhibitory activity towards cdk4. EMBO J. 15: 1607–1614.
Pise-Masison, C. A., Choi, K.-S., Radonovich., M., Dittmer, J., Kim, S.-J., and Brady, J. N. (1998) Inhibition ofp53 transactivation function by the human T-cell lymphotropic virus type 1 tax protein. J. Virol. 72: 1165–1170.
Reid, R. L., Lindholm, P. F., Mireskandari, A., Dittmer, J., and Brady, J. N. (1993) Stabilization of wild-type p53 in human T-lymphocytes transformed by HTLV-I. Oncogene 8: 3029–3036.
Cereseto, A., Diella, F., Mulloy, J. C., Cara, A., Michieli, P., Grassmann, R., et al. (1996) p53 functional impairment and high p2lWAV1/CIP1 expression in human T-cell lymphotropic/leukemia virus type I-transformed T cells. Blood 88: 1551–1560.
Kinoshita, T., Shimoyama, M., Tobinai, K., Ito, M., Ito, S., Ikeda, S., et al. (1989) Detection of mRNA for the tax i/rex i gene of human T cell leukemia virus type I in fresh peripheral blood mononuclear cells of adult T-cell leukemia patients and viral carriers by using the polymerase chain reaction. Proc. Natl. Acad. Sci. USA 86: 5620–5624.
Hoppe-Seyler, F. and Butz, K. (1995) Molecular mechanisms of virus-induced carcinogenesis: the interaction of viral factors with cellular tumor suppressor proteins. J. Mol. Med. 73: 529–538.
Walboomers, J. M. M., de Roda Husman, A.-M., van den Brule, A. J. C., Snijders, P. J. F., and Meijer, C. J. L. M. (1994) Detection of genital human papillomavirus infections: critical review of methods and prevalence studies in relation to cervical cancer. In: Cervical Cancer ( Stern, P., ed. ), Oxford University Press, pp. 41–71.
Carbone, M., Rizzo, P., and Pass, H. I. (1997) Simian virus 40, poliovaccines and human tumors: a review of recent developments. Oncogene 15: 1877–1888.
Dörries, K. (1997) New polyomavirus-induced disease. Adv. Virus Res. 48: 205–261.
Greaves, M. F. and Alexander, F. E. (1993) An infectious etiology for common acute lymphoblastic leukemia in childhood? Leukemia 7: 349–360.
Schiller, J. T. and Lowy, D. R. (1996) Papillomavirus-like particles and HPV vaccine development. Semin. Cancer Biol. 7: 373–382.
Tindle, R. W. (1996) Human papillomavirus vaccines for cervical cancer. Curr. Opin. Immunol. 8: 643–650.
Chang, M. H., Chen, C. J., Lai, M. S., Hsu, H. M., Wu, T. C., Kong, M. S., et al. (1997) Universal hepatitis B vaccination in Taiwan and the incidence ofhepatocellular carcinoma in children. Taiwan childhood hepatoma study group. N. Engl. J. Med. 336: 1855–1859.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media New York
About this chapter
Cite this chapter
Hoppe-Seyler, F., Butz, K. (2002). Viral Mechanisms of Human Carcinogenesis. In: Coleman, W.B., Tsongalis, G.J. (eds) The Molecular Basis of Human Cancer. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-125-1_12
Download citation
DOI: https://doi.org/10.1007/978-1-59259-125-1_12
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-107-3
Online ISBN: 978-1-59259-125-1
eBook Packages: Springer Book Archive